Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether protective anti-HB serum levels are
maintained after 6 months of uninterrupted treatment with IGIV-HB Grifols, a new specific
hepatitis B immune globulin, in patients having previously undergone liver transplantation.
Phase:
Phase 3
Details
Lead Sponsor:
Instituto Grifols, S.A.
Treatments:
Antibodies Hepatitis B Antibodies Immunoglobulins Immunoglobulins, Intravenous